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Objective—To assess the effect of oral and injectable contraceptive use compared to non-
hormonal contraceptive use on HIV acquisition among Southern African women enrolled in a 
microbicide trial.
Study Design—Prospective cohort study using data from women enrolled in HIV Prevention 
Trials Network (HPTN) protocol 035. At each quarterly visit, participants were interviewed about 
self-reported contraceptive use and sexual behaviors and underwent HIV testing. Cox proportional 
hazards regression was used to assess the effect of injectable and oral hormonal contraceptive use 
on HIV acquisition.
Results—The analysis included 2,830 participants, of whom 106 became HIV infected (4.07 per 
100 person-years.) At baseline, 1,546 (51%) participants reported using injectable contraceptives 
and 595 (21%) reported using oral contraceptives. HIV incidence among injectable, oral and non-
hormonal contraceptive method users was: 4.72, 2.68 and 3.83 per 100 person-years, respectively. 
Injectable contraceptive use was associated with a non-statistically significant increased risk of 
HIV acquisition (adjusted hazard ratio [aHR] = 1.17; 95% confidence interval [CI] 0.70, 1.96), 
while oral contraceptive use was associated with a non-statistically significant decreased risk of 
HIV acquisition (aHR=0.76; 95% CI 0.37,1.55).
Conclusion—In this secondary analysis of randomized trial data, a marginal, but non-
statistically significant, increase in HIV risk among women using injectable hormonal 
contraceptives was observed. No increased HIV risk was observed among women using oral 
contraceptives. Our findings support the World Health Organization’s recommendation that 
women at high risk for acquiring HIV, including those using progestogen-only injectable 
contraception, should be strongly advised to always use condoms and other HIV prevention 
measures.
Keywords
hormonal contraception; HIV infection; injectables; oral contraceptive pills; Southern Africa; 
women
INTRODUCTION
Access to safe and effective contraceptive methods is one of the cornerstones of 
reproductive health. Use of these methods has contributed to reductions in unintended 
pregnancies and improvements in maternal and child health outcomes throughout the 
world.1 Approximately 140 million women use hormonal contraception (HC) globally, with 
100 million using oral contraceptive pills (OCPs) and 40 million using injectable 
contraceptives.2 After two decades of investigation, the relationship between injectable and 
oral HC and HIV acquisition remains unclear.3-8 A prospective study of heterosexual HIV-
serodiscordant couples from seven African countries enrolled in an HIV prevention trial, 
which reported that women using injectable contraceptives had a 2.05-fold increased risk of 
HIV acquisition (95% CI 1.04, 4.04), has re-focused attention to this question.9 Despite 
these findings and findings from several other studies that reported an increased risk of HIV 
acquisition among injectable HC users,10-15 the overall body of evidence assessing this 
relationship is still inconclusive,5-8 leading the World Health Organization (WHO) to call 
for further research on this topic.4 Continued evaluation of the association between 
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injectable and oral HC and HIV acquisition through well-designed secondary analyses using 
data from rigorously conducted, prospective HIV prevention studies has the potential to 
improve our understanding of this important public health issue.16 Here we report the 
findings from a secondary analysis that assessed the effect of injectable and oral 
contraceptive use on HIV acquisition among women from 4 southern African countries 
enrolled in the HIV Prevention Trials Network (HPTN) 035 microbicide trial.
METHODS
Study design, population and procedures
The HPTN 035 trial was a phase II/IIB, four-arm, multisite, randomized, controlled trial 
comparing BufferGel and 0.5% PRO 2000 gel against two comparator arms 
(hydroxycellulose [HEC] placebo gel and no gel) for HIV prevention (#NCT00074425). 
Detailed trial methods have been described.17 Briefly, between 2005-2008, women from 
five countries (Malawi, South Africa, USA, Zambia, and Zimbabwe) were enrolled and 
followed for a minimum of 12 months and a maximum of 30 months, depending on 
enrollment date. Eligible women were at least 18 years of age, HIV-1 seronegative, non-
pregnant and sexually active. All institutional review boards approved the trial at each site 
and all participants provided written informed consent.
Participants received a comprehensive HIV prevention package that included ongoing HIV 
risk reduction counseling, free male latex condoms, and diagnosis and treatment of sexually 
transmitted infections (STIs) throughout the trial. Use of contraception was not required for 
study participation; however, participants at all research sites received contraceptive 
methods counseling. Participants in Malawi, Zambia and Zimbabwe were offered free 
contraceptive services at the research sites, while participants in South Africa were provided 
referrals to the nearest health center offering contraceptive services.
At monthly follow-up visits, a urine pregnancy test was performed. At quarterly visits, data 
were collected on self-reported condom use, sexual behaviors and contraceptive use 
(participants were asked “Which family planning method or methods are you currently 
using?”). Data on brand of injectable or oral contraceptives was not available. If a 
participant reported a change in method since her last visit, the self-reported date of change 
was systematically recorded on the medications log form. Blood was collected for HIV 
serologic testing at the quarterly visits. Herpes simplex virus type 2 (HSV-2) was evaluated 
at baseline and study exit visits.
Laboratory procedures
HIV-1 infection status was determined using a standardized algorithm, with initial testing 
conducted using rapid tests and confirmatory testing using Western blot.17 HSV-2 testing 
was performed using the HerpesSelect-2 EIA (Focus Technologies; Cypress, California, 
USA). Vaginal saline microscopy was performed for the presence of motile trichomonads 
for diagnosis of Trichomonas vaginalis. Urine specimens were tested for Chlamydia 
trachomatis and Neisseria gonorrhoeae annually using BD ProbeTec ET (Becton 
Dickinson; Franklin Lakes, New Jersey, USA).
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Our primary aim was to estimate the association between self-reported injectable (depot 
medroxyprogesterone acetate [DMPA] or norethisterone oenanthate [NET-EN]) or OCP use 
and HIV acquisition risk among African women enrolled in HPTN 035. The primary 
outcome was detection of HIV-1 infection. Participants who reported using contraceptive 
implants were excluded from the analysis due to small numbers. In addition, we excluded 
women enrolled at the US site as there were no HIV infections observed at that site. To 
avoid potential bias from informative censoring this analysis was limited to the first 12 
months of follow-up for each participant, which was the minimum planned length of follow-
up. Pearson’s chi-square test was used to assess categorical variables (unstratified) at 
enrollment. The Cochran-Mantel-Haenszel test was used to test the association between 
categorical variables and baseline contraceptive use stratified by site. Cox proportional 
hazards (PH) regression models stratified by site were used to assess the effect of injectable 
and OCP use versus non-HC methods (male condoms, surgical sterilization, or no 
contraceptive method) on HIV acquisition, with contraceptive use included in the models as 
a time-varying characteristic. Pregnancy incidence was calculated by contraceptive method 
(excluding those who reported having a tubal ligation) and participants were censored at 
their first positive pregnancy test or at the 12-month of follow-up visit. Participants were 
classified as being exposed to a contraceptive method if they reported use of the method at 
the quarterly follow-up visit. If a participant reported a change in method since her last visit 
quarterly, the self-reported date of change (recorded on the medications log form) was used 
to indicate initiation of exposure to the new method. If a participant missed a visit, time-
varying covariates were imputed using last value carried forward. Age, marital/co-habiting 
status, HSV-2 status and unprotected sex were included in the multivariable model based on 
a priori assumptions. Additional potential confounding factors were considered for inclusion 
in the final model if they were related to both HC use (at baseline or during follow-up) and 
HIV acquisition (Cochran-Mantel-Haenszel test stratified by site using an alpha level 
<0.10).
We repeated the above analyses separately stratifying by age category (<25 years versus 
≥25) and baseline HSV-2 status.12,18 A likelihood ratio test was used to test for effect 
modification. We evaluated the sensitivity of our findings with regard to pregnancy by 
adjusting for pregnancy rather than censoring follow-up at the time of pregnancy detection. 
Due to differences in demographic and clinical characteristics by site, including differences 
in HC use and HIV incidence, we conducted an exploratory analysis restricted to 
participants enrolled at the South African sites. These sites contributed the majority of HIV 
seroconversions and participant follow-up and we hypothesized that participants from these 
sites may be more similar with respect to measured and unmeasured characteristics that 
affect HIV acquisition risk. Sub-group analyses were not performed for other countries due 
to low HIV incidence and limited contraceptive variability. All statistical tests were assessed 
using a 2-sided α of 0.05. Analyses were conducted using Stata version 12.0 (StataCorp, 
Inc., College Station, Texas, USA).
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Among 3,099 participants enrolled in HPTN 035, we excluded 200 participants from the US 
and 34 participants who did not attend any follow-up visits. An additional 35 participants 
who reported using contraceptive implants were excluded, leaving 2,830 participants for 
analysis. Baseline demographic and clinical characteristics are presented in Table 1. Several 
baseline characteristics varied greatly across sites. Overall, most participants reported living 
with a partner (70%); however, the proportion varied substantially by site (range: 11-99%). 
The majority of participants reported having only one sex partner, with only 43 (2%) 
reporting more than one partner in the 3 months prior to enrollment. Less than half (42%) of 
participants were HSV-2 seropositive. At enrollment, HC use was high, with 2,051 (72%) 
participants reporting HC use (injectable or OCP). However, HC methods varied widely 
across sites (Table 1). Many of the same baseline factors that varied significantly across sites 
were also associated with baseline contraception method (Table 2).
Demographic, clinical and behavioral characteristics by contraceptive use at each quarterly 
follow-up visit were similar to those reported at baseline (data not shown). Among 
participants not using HC at baseline, there were 281 instances of initiation of an injectable 
method, and 154 instances of OCP initiation. Among participants using HC at baseline, the 
majority of participants did not change methods during the trial (1,707/2,051 [83%]), with 
344 instances of a switching from the initial HC method to another HC method (184 
instances of switching from injectable to OCP; and 160 instances of switching from OCP to 
injectable). The overall pregnancy incidence was 11.34/100 person-years. Participants who 
reported using injectables had the lowest pregnancy rate (3.56/100 person-years), followed 
by OCP users (19.64/100 person-years), and participants who reported non-HC (excluding 
those with tubal ligation) = 31.62/100 person-years.
Over 2,605 person-years of follow-up, there were 106 incident HIV infections (overall HIV 
incidence of 4.07/100 person-years). HIV incidence varied by country and was highest in 
South Africa (6.76/100 person-years; 95% confidence interval [CI] 5.30, 8.61), followed by 
Zambia (3.42/100 person-years; 95% CI 1.84, 6.36), Malawi (2.82/100 person-years; 95% 
CI 1.49, 3.50) and Zimbabwe (2.32/100 person-years; 95% CI 1.25, 4.32). Compared to 
non-HC, injectable use was associated with an increased risk of HIV acquisition (adjusted 
hazard ratio [aHR] = 1.17; 95% CI 0.70, 1.96), however, the association was not statistically 
significant. In contrast, OCP use was associated with a decreased risk of HIV acquisition 
that was also not statistically significant (aHR=0.76; 95% CI 0.37,1.55) [Table 3]. 
Sensitivity analyses adjusting for pregnancy rather than censoring at the first pregnancy 
showed similar results (data not shown). Additional analyses showed no evidence of effect 
modification by age category (<25 versus ≥25 years) [pinteraction=0.51] or baseline HSV-2 
status (pinteraction=0.51) [Table 3]. Among South African participants, there was a trend 
towards a two-fold increased HIV risk among women using injectables in unadjusted 
analyses, with a slight attenuation of the association after controlling for potential 
confounders (Table 3). No association between OCP and HIV acquisition was observed.
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In this secondary analysis, we did not observe a significant increased risk of HIV acquisition 
among women using injectable or oral contraceptive methods. Our overall findings are 
similar to several other secondary analyses using data from women enrolled in HIV 
prevention trials in Africa that reported modest increases in HIV acquisition risk among 
women using injectable HC.7,19,20 No statistically significant interactions between baseline 
age or HSV-2 status and HC method were observed.12,18 Our primary results differed from 
those reported in a prospective analysis of HIV serodiscordant couples participating in the 
Partners in Prevention HSV/HIV Transmission study, where women who reported using 
injectables had a significant increased HIV risk compared to women using non-HC.9,21
One feature of our study was the high rate of injectable use reported at baseline and 
throughout the study. Specifically, 51% of participants reported using injectables at 
enrollment. This level of use was similar to the levels reported in analyses from other 
microbicide trials,13,14,20 but substantially higher than what was reported in the Partners 
study (baseline injectable use=13%).9,20 OCP use was similar to levels observed by others 
(range: 4-22%).9,13-15,20,22,23 Despite frequent contraceptive counseling, pregnancy was 
also common. We observed high pregnancy rates among women reporting OCP use versus 
OCP failure rates reported by others,24 suggesting that adherence to OCP was low. It is 
possible that we didn’t observe an association between OCP use and HIV risk due to lower 
adherence of oral contraceptives.
Another feature was the high degree of heterogeneity in demographic, behavioral and 
clinical characteristics between study sites, including HIV incidence. In a multisite trial, it is 
desirable to have some heterogeneity between sites in order to demonstrate that an 
intervention is effective in a variety of populations; however, this heterogeneity can be 
problematic in secondary analyses where the exposure (HC use) is not balanced across sites. 
Contraceptive method choice was highly dependent on site. At some sites, uptake of OCP 
was <10%, a rare exposure in a population with a rare outcome, thus limiting our ability to 
assess the relationship between OCP and HIV acquisition by site. Several potential 
confounders were highly correlated with site and may have different confounding 
relationships across sites. In addition, HIV incidence varied across sites and was highest in 
South Africa at 6.76% compared to 2.51% in all other countries combined. Differential 
exposure to HIV-infected partners is likely to have varied by site, further contributing to site 
heterogeneity in HIV acquisition risk. Although our analysis attempted to address 
heterogeneity by stratifying by site and adjusting for potential confounders, residual 
confounding may be present. We attempted to address this further by performing an analysis 
restricted South African sites, where we observed a trend toward an increased risk of HIV 
acquisition among injectable users in unadjusted analyses, which attenuated slightly after 
adjustment for potential confounders. Others have reported differences by country in the 
effect of HC on HIV risk.18 If a true biologic effect of HC use exists, then effect estimates 
should be consistent across countries. However, confounding by site or country may 
contribute to differences across populations. Careful assessment of and adjustment for 
potential confounders is critical in order to attempt to achieve unbiased estimates of HIV 
risk.
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Several recent studies that assessed the effect of HC on HIV acquisition have used marginal 
structural models (MSM),25,26 in addition to Cox models, to attempt to address bias that 
may be present as a result of time-dependent confounding.9,12,15,19,20 In these studies, 
results from MSM models have been similar to those generated by Cox models. The 
similarities could be due to the absence of strong time-dependent confounding or due to 
violation of one more of the assumptions required to achieve unbiased estimates with 
MSM.27,28 One key assumption is the positivity assumption, which states that there must be 
both exposed and unexposed individuals at every level of a confounder. For example, in 
hormonal contraception and HIV acquisition analyses, the positivity assumption may be 
violated if a participant becomes pregnant, since pregnant women are not exposed to 
hormonal contraception although they continue to be at risk for HIV.28 Due to concerns over 
violation of the positivity assumption with regard to pregnancy in our data, we did not feel it 
was appropriate to perform MSM.
The findings from this analysis should be interpreted in the context of several limitations. 
Among South African participants, data were not available on the specific type of injectable 
method used (DMPA versus NET-EN); therefore, we cannot assess the potential differing 
effects of these two injectable methods on HIV acquisition. Data on contraceptive use was 
obtained by self-report and data on partner characteristics, including HIV status, were not 
collected. Although we adjusted for potential confounders, there was heterogeneity across 
sites and the potential for residual confounding. In this study, participants underwent 
quarterly HIV testing and assessment of contraceptive methods and potential confounders, 
including condom use; future studies will be strengthened by more frequent assessments of 
HC use, potential confounders and HIV status in order to allow for a more precise 
evaluation of the HC and HIV acquisition relationship.16
In summary, we observed a marginal, but not statistically significant increase in HIV risk 
among women using injectable HC, which was similar in multiple sensitivity analyses. 
Among women from South Africa, the magnitude of HIV risk among injectable HC users 
was greater but did not reach statistical significance. We did not observe an increased risk of 
HIV acquisition among women using OCP in any of our analyses. Rather, effect estimates 
indicated a modest decrease in HIV acquisition; although, these associations also did not 
achieve statistical significance. Continued research on the relationship between widely used 
contraceptive methods and HIV acquisition is essential. In addition, the uncertainty 
regarding the impact of injectable contraception on HIV acquisition risk coupled with the 
high pregnancy rate among OCP users observed in our analysis highlight the urgent need to 
expand the contraceptive method mix by increasing access to long acting reversible 
contraceptive (LARC) methods, such as intrauterine devices and hormonal implants, and 
developing low-dose hormonal methods. The effect of these long-acting contraceptive 
methods on HIV risk requires evaluation. Despite frequent counseling and access to 
condoms, the HIV incidence in our study was high, particularly in South Africa. Given this 
high incidence, our findings support the WHO’s recommendation that women at high risk 
for HIV, including those using progestogen-only injectable HC, should be strongly advised 
to always use condoms in addition to other HIV prevention measures.4
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Among Southern African women participating in an HIV prevention trial, women using 
injectable hormonal contraceptives had a modest increased risk of HIV acquisition, 
however this association was not statistically significant. Continued research on the 
relationship between widely used hormonal contraceptive methods and HIV acquisition 
is essential.
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 < 25 years 750 (52) 248 (42) 340 (44)
 25-35 years 674 (46) 335 (56) 329 (45)
 ≥ 35 years 32 (2) 12 (2) 90 (11)
Living with partner 1055 (72) 525 (88) 405 (52) <0.001
Education (> primary school) 783 (54) 459 (77) 468 (60) <0.001
Number of live births <0.001
  0 23 (2) 16 (3) 107 (14)
  1-2 910 (63) 427 (72) 358 (46)
  ≥ 3 523 (36) 152 (25) 314 (40)
More than 1 sex partner in the past 3 months
3 19 (1) 2 (<1) 22 (3) <0.001
Condom used at last vaginal sex act 924 (63) 458 (77) 556 (71) <0.001
HSV-2 seropositive 614 (42) 210 (35) 364 (47) <0.001
1
Use of male condoms, surgical sterilization, or no contraceptive method.
2
Cochran-Mantel-Haenszel test stratified by site.
3
Report of sexual activity in the last 3 months was required in order to be eligible for enrollment.




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Contraception. Author manuscript; available in PMC 2017 January 01.
